缬沙坦对血液透析患者血钾影响.docVIP

缬沙坦对血液透析患者血钾影响[摘要] 目的 探讨缬沙坦对血液透析患者血钾的影响。 方法 肾衰竭血液透析患者80例平分为两组，治疗组与对照组各40例，两组均采用血液透析治疗，治疗组在透析治疗的基础上服用缬沙坦分散片。 结果 两组治疗前的血钾水平分别为（6.5±2.3） mmol/L和（6.9±2.2） mmol/L；治疗后对照组血钾为（10.8±3.3） mmol/L，治疗组为（6.8±1.2）mmol/L，表明治疗前两组血钾对比无明显差异（t = 1.253，P ＞ 0.05），治疗后治疗组血钾水平明显低于对照组（t = 5.963，P ＜ 0.05）。结论 缬沙坦应用于血液透析患者能在维持疗效的基础上，无升高血钾作用，从而提高保护效果，值得推广应用。 [关键词] 缬沙坦；血液透析；血钾 [中图分类号] R459.5 [文献标识码] B [文章编号] 1673-9701（2012）03-0159-02 Effects of valsartan on the impact of potassium in hemodialysis patients AN Xin LIU Yan Xinjiang Uygur Autonomous Region Karamay City Central Hospital, Karamay 834000，China [Abstract] Objective To investigate the effect of of valsartan on the impact of potassium in hemodialysis patients. Methods Eighty patients with renal failure hemodialysis patients were equally divided into two groups-the hemodialysis treatment, the treatment group were added the valsartan treatment. Results The serum potassium in the wo groups before treatment were (6.5±2.3) mmol/L and (6.9±2.2) mmol/L, after treatment, the serum potassium of the the control group was (10.8±3.3) mmol/L, so that was (6.8±1.2) mmol/L in the treatment group, the two groups before treatment showed no difference (t=1.253, P ＞ 0.05), after treatment, the serum potassium levels of the treatment group were significantly lower than the control group (t=5.963, P＜0.05). Conclusion Valsartan can keep the efficacy that be used for hemodialysis patients, and has role of no rise hyperkalemia, thereby enhance the protective effect, should be widely applied. [Key words] Valsartan; Hemodialysis;Potassium 慢性肾衰竭是常见的临床疾病，发病率甚至可以达到人群的7%。慢性肾衰竭患者由于长期进行血液透析和肾脏功能的进一步减退，此类人群承受的经济压力和心理压力较大，生活质量相对于正常人群较差，且死亡率较高[1]。慢性肾衰竭病情的进一步发展会逐渐地发展成为尿毒症，慢性肾衰竭患者死亡的大部分原因是尿毒症，多需要血液透析治疗[2]。近些年来随着肾素-血管紧张素系统及血管紧张素受体研究的不断深入，发现肾素-血管紧张素系统的激活在心力衰竭的发生、发展中起着重要的作用[3]。本文探讨了缬沙坦对血液透析患者血钾的影响，现报道如下。 1 资料与方法 1.1 一般资料 选择在我院心血管科2008年2月～2010年12月进行血液透析的80例患者，男52例，女28例；年龄35~72岁，平均（ 56.23±11.42）岁。均签订知情同意书，并积极配合。根据入院顺序，将上述患者分为治疗组与对照组各40例，两组患者的性别、年龄等